

# Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



## Final Appraisal Recommendation

Advice No: 1318 – September 2018

**Levonorgestrel (Kyleena®) 19.5 mg intrauterine delivery system**

**Limited submission by Bayer plc**

### Recommendation of the All Wales Medicines Strategy Group

**Levonorgestrel (Kyleena®) is recommended as an option for use within NHS Wales for contraception for up to five years.**

#### Additional note(s):

- Levonorgestrel (Kyleena®) should be prescribed by brand name to avoid medication errors.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3582), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –  
1318: Levonorgestrel (Kyleena®) 19.5 mg intrauterine delivery system  
September 2018